Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease

No clinical trials have been specifically designed to compare medical treatments after surgery in Parkinson's disease (PD).

[1]  P. Salin,et al.  Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[2]  A. Benabid,et al.  Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson disease , 2019, Neurology.

[3]  M. T. Pellecchia,et al.  Parkinson’s disease management and impulse control disorders: current state and future perspectives , 2019, Expert review of neurotherapeutics.

[4]  P. Krack,et al.  Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  C. McIntyre,et al.  StimVision Software: Examples and Applications in Subcallosal Cingulate Deep Brain Stimulation for Depression , 2018, Neuromodulation : journal of the International Neuromodulation Society.

[6]  N. Jodoin,et al.  Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[7]  A. Fasano,et al.  Medical Management of Parkinson’s Disease after Initiation of Deep Brain Stimulation , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[8]  A. Fasano,et al.  Eligibility Criteria for Deep Brain Stimulation in Parkinson’s Disease, Tremor, and Dystonia , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  Marina Picillo,et al.  Programming Deep Brain Stimulation for Parkinson's Disease: The Toronto Western Hospital Algorithms , 2016, Brain Stimulation.

[10]  M. T. Pellecchia,et al.  Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[11]  Antonio Daniele,et al.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.

[12]  A. Costello,et al.  Changes in the non-motor symptom scale in Parkinson’s disease after deep brain stimulation , 2011 .

[13]  L. Schöls,et al.  CSF Aβ42 and tau in Parkinson's disease with cognitive impairment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[14]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[15]  M Zappia,et al.  International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease , 2009, Neurology.

[16]  E. Tolosa,et al.  A reassessment of risks and benefits of dopamine agonists in Parkinson's disease , 2009, The Lancet Neurology.

[17]  Daniel Weintraub,et al.  Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[18]  L. Lopiano,et al.  Antiparkinsonian therapy modifications in PD patients after STN DBS: a retrospective observational analysis. , 2008, Parkinsonism & related disorders.

[19]  J. Bergquist,et al.  Irreversible motor impairment in young addicts – ephedrone, manganism or both? , 2007, Acta neurologica Scandinavica.

[20]  G. Deuschl,et al.  Deep brain stimulation: Postoperative issues , 2006, Movement disorders : official journal of the Movement Disorder Society.

[21]  Bettina Schrader,et al.  Most effective stimulation site in subthalamic deep brain stimulation for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[22]  C Trenkwalder,et al.  The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[23]  Niels Sunde,et al.  Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Molinuevo,et al.  Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. , 2000, Archives of neurology.

[25]  P. Remy,et al.  Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT‐PD) , 1999, Movement disorders : official journal of the Movement Disorder Society.

[26]  R. Fitzpatrick,et al.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease , 1995, Quality of Life Research.

[27]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[28]  R. Marin,et al.  Reliability and validity of the apathy evaluation scale , 1991, Psychiatry Research.

[29]  B. Kluger.  Fatigue in Parkinson's Disease. , 2017, International review of neurobiology.

[30]  C R Butson,et al.  StimExplorer: deep brain stimulation parameter selection software system. , 2007, Acta neurochirurgica. Supplement.

[31]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.